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Summary. Hepatic arterial chemotherapy represents a 
means of selectively exposing hepatic tumor to cytotoxic 
agents. Although 5-fluoro-2'-deoxyuridine has been shown 
to generate a higher response rate in the treatment of col- 
orectal liver metastases than that achieved by intravenous 
infusion, responses are largely incomplete and rarely of 
long duration. This review describes the rationale for the 
use of the thymidine analogs 5-bromo-2'-deoxyuridine and 
5-iodo-2'-deoxyuridine in hepatic arterial infusions and in- 
dicates how combination therapy adding radiotherapy, 
specifically with hepatic arterially administered yttrium-90 
microspheres, might generate a new, more efficient and ef- 
fective therapeutic approach. 
Rationale 
Cancer frequently grows within the liver and such growth 
is often a major source of morbidity and mortality. Al- 
though surgical resection can cure about one-third of pa- 
tients having a solitary tumor nodule in the liver, it ap- 
pears that less than 5% of patients with hepatic cancers fall 
into this category where resection can be attempted [2, 3, 
13, 15, 29, 30]. Although the greatest benefit of other re- 
gional approaches aimed at the eradication of hepatic tu- 
mors would be anticipated to accrue in the small group of 
patients who truly have tumor confined to liver (but who 
are unresectable because of technical considerations), 
significant palliation might be possible and represent a 
worthwhile goal in the large number of patients with ex- 
tensive tumor within the liver. In addition, systemic ther- 
apies might have more impact when applied to microscop- 
ic extrahepatic disease in this last group of patients. 
Accordingly, there has been a great deal of interest in 
the treatment of hepatic cancer within the oncology com- 
munity. Although hepatic arterial chemotherapy had been 
practiced previously in a limited number of centers, the 
development of a more convenient method for hepatic ar- 
terial therapy utilizing an implantable drug delivery sys- 
tem has led to the implantation of approximately 20000 of 
such systems at more than 1400 'centers' over the past 
5 years. It is clear that recent interest in hepatic arterial che- 
motherapy as a treatment for hepatic cancer has been 'de- 
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vice-driven' and not 'drug-driven' inasmuch as the agent 
used in essentially all hepatic arterial infusions has been 
5-fluoro-2'-deoxyurdine (FdUrd), a drug that has been 
available for over 20 years. Recently conducted random- 
ized studies from Sloan Kettering and the Northern Cali- 
fornia Oncology Group indicate that FdUrd, given by the 
hepatic arterial route, generates a higher objective re- 
sponse rate than an equitoxic dose of intravenous FdUrd 
given on the same two-weeks-out-of-four continuous infu- 
sion schedule [19, 23]. Unfortunately, as a single agent, he- 
patic arterial FdUrd alone fails to induce tumor regression 
in about half of the patients treated, and the half that show 
an objective response frequently fail within the liver after 
6 -8  months of treatment [32]. 
Thus, devices (drug-delivery systems) now exist mak- 
ing protracted (hepatic arterial) drug infusions easier and 
more reliable. This technical capability, the demonstrated 
interest in hepatic arterial therapy as a treatment ap- 
proach, the shortcomings of FdUrd, and the limitations 
imposed by a lack of other agents can be seen as factors 
driving the development of new and potentially more ef- 
fective drug therapies using the hepatic arterial route of 
administration. It is evident that additional clinical pro- 
grams are needed for hepatic arterial therapy. 
A major rationale for hepatic arterial therapy relates to 
the importance of the hepatic artery in providing the blood 
supply to tumors growing within the liver. Recent elegant 
studies from the group at Sloan Kettering have confirmed 
the predominence of the hepatic artery as the source of nu- 
trient blood flow to hepatic tumors [36] and that FdUrd 
uptake into human liver tumors is more than tenfold great- 
er with hepatic arterial versus portal venous administra- 
tion [38]. 
Pharmacokinetic theory predicts that it should be pos- 
sible to generate higher and more selective drug exposure 
for intrahepatic tumors (fed by the hepatic artery) by di- 
rect hepatic arterial infusion of agents that have appropri- 
ate pharmacokinetic properties [4, 6]. In particular, drugs 
which have a high total body clearance and a high hepatic 
extraction are most appropriate pharmacokinetically. Ap- 
propriately administered, hepatic arterial chemotherapy 
may generate higher levels of drug exposure for liver tu- 
mors than systemic tolerance would allow by intravenous 
administration, thereby allowing extension of the dose-re- 
sponse curve for antitumor activity. As illustrated in Fig. 1, 
hepatic tumor exposure may be high with concurrent low 
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Fig. 1. Hypothetical dose-response curvewith normaltissue ( ) 
and tumor ( . . . . .  ) nearly superimposed. With intravenous ther- 
apy (©), tumor and normal tissue see same dose. With regional 
chemotherapy (uncircled arrows), regional tumor exposure is 
10-100 x exposure to rest of body 
sion. With intravenous infusion at levels as high as those 
achieved in the liver with hepatic infusion, lethal toxicity 
may result as systemic dose-limiting tissues get too high an 
exposure. 
As noted previously, hepatic arterial chemotherapy has 
played an important role in the development of drug-de- 
livery systems for safe and reliable protracted, continuous 
infusion therapy. For drugs such as the nucleic acid pre- 
cursor analog FdUrd, protracted exposure plays a crucial 
role in determining activity. At the cellular level, exposure 
during S phase is necessary inasmuch as DNA synthesis is 
a major target for such antimetabolites. Thus, extracellular 
drug levels must be maintained for numerous cell cycles to 
produce maximum effect in non-synchronized cells in cul- 
ture (in vitro) or in tissues (in vivo). From a pharmacokin- 
etic point of view, the high clearance and short t,/2 of many 
nucleic acid analogs necessitate constant infusion in vivo 
to maintain plasma (and extracellular) drug levels. 
Hepatic arterial chemotherapy thus represents a meth- 
od both for extending drug exposure to higher levels and 
for maintaining controlled drug levels for prolonged, de- 
fined time periods in vivo. As such, hepatic arterial che- 
motherapy represents an unique opportunity to extend stud- 
ies on the selective effects of controlled drug exposure in 
cell cultures and animal models to patients with hepatic 
cancers. The relatively high tolerance of the liver to chemo- 
therapeutic drugs, the minimal DNA synthesis in the liv- 
er and, the ability to monitor toxic and therapeutic effects 
readily within in the liver contribute to the rationale sub- 
Table !. Relevant factors favoring the use of 5-bromo-2'-deoxy- 
uridine/5-iodo-2'-deoxyuridine 
1. Potent cytotoxic agents (and radiosensitizers) 
2. Crucial target effect to DNA thymine replacement by the 
analog 
3. DNA incorporation a function of 
(a) DNA synthetic rates 
(b) Exposure (concentration, time) 
4. Pharmacokinetic properties should allow increased exposure 
with regional intra-arterial administration 
5. Selective inhibition of competing endogenous thymidylate 
synthesis may increase DNA incorporation of analog 
stantiating the use of hepatic arterial chemotherapy with 
DNA synthesis antimetabolites as a means to extend po- 
tentially meaningful in vitro observations into the clinical 
setting. 
5-Bromo-2'-deoxyuridine (BrdUrd) and 
5-iodo-2'-deoxyuridine (IdUrd) as new 
rational agents for hepatic arterial infusion 
As described below and noted in Table 1, there is evidence 
that the thymidine analogs, BrdUrd and IdUrd, represent 
rational agents to study in hepatic arterial therapeutics. Al- 
though these agents have existed for a long time, they have 
not previously been tested in hepatic arterial infusion. Re- 
cent pharmacokinetic data on these agents given intrave- 
nously has shown that both of these drugs have pharmaco- 
kinetic parameters (see below) making them reasonable to 
investigate in regional infusions [27, 37]. In addition, al- 
though BrdUrd and IdUrd are directly cytotoxic to pro- 
liferating cells, it is likely that the excellent radiosensitiz- 
ing properties they possess (upon incorporation into 
DNA) [111 will lead to continued expanded interest in 
their regional administration. Hepatic arterial chemothera- 
py with these agents, having incorporation into cellular 
DNA as a crucial target effect, represents an excellent 
opportunity to see whether in vitro/in vivo correlations 
are possible and whether they will facilitate application of 
biochemical pharmacology to clinical experimental thera- 
peutics. In the long term, it appears probable that pro- 
grams rationally designed would give rise to new, more ef- 
fective regimens demonstrated by higher complete re- 
sponse rates and shorter treatments. 
There are many variables that are probably extremely 
important to the design of therapies with BrdUrd and 
IdUrd having the best chance of success (Table 2). Al- 
though BrdUrd and IdUrd are both thymidine analogs, in 
which the 5-methyl group on the pyrimidine ring is re- 
placed by bromine and iodine respectively, there is consid- 
erable evidence demonstrating that BrdUrd and IdUrd be- 
have differently in biological systems. Stereochemical con- 
siderations would suggest that BrdUrd is the better thymi- 
dine analog since the van der Waals radius of bromine 
(0.195 nm) is closer to that of the methyl group (0.20 nm) 
of thymine than is the radius of iodine (0.215 nm). Consis- 
tent with this premise is evidence that for molar equivalent 
analog exposure, the percentage thymine replacement (in 
one human cell line) was greater for BrdUrd (18%) than 
for IdUrd (9%) [12]. On the other hand, per given level of 
thymine replacement, IdUrd generates considerably more 
cytotoxicity and X-ray sensitization in cultured cells 
[7, 12]. In cultured cells, BrdUrd incorporation leads to more 
ultraviolet sensitization than does IdUrd. In mouse tongue 
epithelial cells in vitro, neither BrdUrd nor IdUrd is stably 
incorporated into DNA and turnover times differ (1.0 days 
Table 2. Important variables in the study of halogenated thymid- 
ine analogs 
BrdUrd versus IdUrd 
Dose rate 
Schedule (duration) 
Route administered (i.a. versus i.v.) 
Modulation (temperature-sensitive inhibitors) 
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for BrdUrd, 3.8 days for IdUrd [21]. Such differences, if 
extrapolated to a clinical setting, would appear relevant to 
the choice and schedule of analog to be used primarily for 
cytotoxic or radiosensitizing effect. 
Recent clinical studies at the National Cancer Institute 
indicate that BrdUrd and IdUrd display several clinically 
relevant differences when administered intravenously to 
patients [25-27, 37]. The total body clearance of BrdUrd 
was found to be 1.5-2.3 I min - l  m -2 and the maximum 
tolerated dose rate and resultant plasma level for a 14-day 
i.v. infusion were 6 0 0 - 8 0 0 m g m - 2 d a y  -1 and 1 IxM re- 
spectively. For IdUrd the total body clearance was found 
to be 0.75 1 rain -1 m -z, and the corresponding maximum 
tolerated dose rate and plasma level (14-day i.v. infusion) 
were 1000 mg m -2 day -1 and 5-6  IxM. These preliminary 
results from the NCI indicate that the human body metab- 
olizes BrdUrd more efficiently with a higher clearance 
than seen with IdUrd. Thus, on the basis of pharmacokin- 
etic considerations, BrdUrd, given in an arterial infusion, 
should generate a twofold to threefold higher regional ad- 
vantage than would a similar IdUrd infusion. On the other 
hand, a higher systemic concentration of IdUrd is tolerat- 
ed in a 14-day intravenous infusion - which data indicate 
that the actual exposure advantage of a BrdUrd regional 
infusion over an IdUrd infusion (at maximum tolerated 
dose rates) would be less than anticipated. 
One approach to gaining control of the many variables 
relevant to BrdUrd and IdUrd is to develop preclinical 
models and to validate them as to their predictability for 
the clinic. For example, preliminary data (Table 3), which 
we have obtained, demonstrate that rabbits [28] and dogs 
may provide pharmacokinetic information predictive of 
results in humans. Clearly, in all three species hepatic arte- 
rial BrdUrd achieves a significant (albeit a calculated esti- 
mate) regional advantage as compared to intravenous in- 
fusion. 
We have applied an animal tumor model, the intrahe- 
patically implanted VX2 tumor in rabbits, to the examina- 
tion of the dependence of DNA incorporation on the sus- 
tained plasma drug level. In this system, the crucial target 
effect, incorporation of BrdUrd into DNA, follows satu- 
rating, non-linear kinetics as defined by a Longmuir type 
equation 
I = Imaxe 
C50+C 
where I = percentage incorporation of BrdUrd into DNA; 
/max = maxium percentage incorporation of BrdUrd; c = 
steady-state plasma concentration of BrdUrd; es0 = plasma 
BrdUrd concentratzion at half-maximal incorporation. 
The curve plotting incorporation into bone marrow always 
lies above that for tumor (Fig. 2) as ascertained in 24-h in- 
travenous infusions with measurements of steady-state sys- 
Table 3. BrdU pharmacokinetics in rabbits, dogs and humans 
Subjects C L r B  Normalized Hepatic Hepatic 
(ml/min) (ml/kg-~min 1) extraction regional 
ratio advantage 
Rabbits 180- 220 45-55 0.66-0.75 30- 50 
Dogs 1000- 1600 33-50 0.90-0.95 100-350 
Humans 2500-3500 35-50 0.75-0.90 40- 100 
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Fig. 2. Predicted incorporation of BrdUrd (BU or BUDR) into 
DNA (thymine replacement of VX2 tumor and of bone marrow) 
assuming tenfold regional exposure advantage such as might be 
achieved through hepatic arterial infusion. Top curves, low dose 
rate; bottom high dose rate. Marrow (©) and tumor (0) incorpo- 
ration falls in each case on pharmacodynamically determined 
curves for marrow and tumor, respectively 
temic arterial plasma levels [39]. These tissue-dependent 
incorporation profiles give rise to an important prediction. 
Although pharmacokinetic parameters may allow a selec- 
tive increase in hepatic tumor exposure with hepatic arteri- 
al infusion, the impact on what actually is most important, 
i.e. DNA incorporation, will be less selective at high than 
at low dose rates. If, for example, one assumes the achieve- 
ment of a tenfold regional advantage, at low dose rates 
(top, Fig. 2), tumor incorporation (filled circle) is greater 
than marrow incorporation (open circle). At high dose 
rates (bottom, Fig. 2), despite higher local BrdUrd levels, 
tumor incorporation (filled circle) is less than marrow 
(open circle). Thus, more is not always better! Pilot data in 
the VX2 system have indicated that the predication is cor- 
rect, showing a decline in selective uptake as the hepatic 
arterial dose rate increases even from 10 mg kg -1 day -1 to 
20 mg kg- 1 day-  1. 
In cultured cells, inhibition of thymidylate synthase re- 
duces endogenous production of thymidine monophos- 
phate and results in increased salvage of exogenous thymi- 
dine or of exogenously provided thymidine analogs. In- 
corporation of the thymidine analog BrdUrd can be in- 
creased as much as tenfold in cultured cells when FdUrd is 
used to inhibit thymidylate synthase via FdUMP forma- 
tion [9]. Recognizing the limitations of intravenous re- 
placement of DNA thymine residues by iodouracil resi- 
dues, the intramural group at the NCI has initiated a 
phase I clinical study of combined intravenous infusion of 
IdUrd with FdUrd. A t  the University of Wisconsin, a 
phase I protocol, involving hepatic arterial infusion of 
IdUrd plus fluorouracil is underway as well [40]. 
Inasmuch as FdUrd and 5-fluorouracil both have phar- 
macokinetic properties leading to an improved regional 
exposure advantage with hepatic arterial infusion, combi- 
nation of FdUrd or fluorouracil with BrdUrd or IdUrd in 
hepatic arterial infusions would appear reasonable. Using 
the rabbit VX2 system, we have found that concurrent ad- 
ministration of FdUrd and fluorouracil at clinically rele- 
vant dose rates does not appreciably change BrdUrd in- 
corporation into replicating marrow cells but does in- 
crease (selectively) incorporation into VX2 some twofold. 
After additional studies of dose range in cell culture and in 
the VX2 system, clinical studies will be initiated using a 
gas chromatography/mass spectrometry assay of incorpo- 
rated BrdUrd combined with the application of two stable 
isotopes of BrdUrd to determine whether FdUrd or fluoro- 
uracil can selectively increase BrdUrd incorporation into 
hepatic tumors versus normal tissues. 
Radiation + hepatic arterial chemotherapy 
Radiation, as a sole modality, has been of modest benefit 
in the treatment of hepatocellular carcinoma. This is chief- 
ly because the tolerance dose to the whole liver for radia- 
tion generally is accepted to be approximately 3500 cGy. 
This conclusion is derived from retrospective reviews, 
chiefly of patients from Memorial Hospital [22] and Stan- 
ford University [34]. These patients were treated once dai- 
ly, typically with one field a day. If  the data from these 
two series are pooled, four out 48 patients treated with less 
than 3500 cGy developed radiation hepatitis: three at 
3500 cGy and one at 3000 cGy. None of these cases was ei- 
ther persistent or fatal. Seven of the 24 patients treated 
with 3500-4000 cGy developed radiation hepatitis, which 
in some cases was persistent or fatal. 
Given these restrictions on the dose of radiation that 
can be safely administered, it can be appreciated why 
there has been little enthusiasm for radiation as a sole mo- 
dality. In one series, 31 patients who were unresectable 
were treated with between 1000 cGy and 3600 cGy, with 
only one survivor past 1 year [8]. Similar results were ob- 
tained in a small randomized trial between combination 
chemotherapy and radiation therapy (3000cGy in 200-cGy 
fractions) followed 2 months later by chemotherapy. Six 
out of eight patients progressed either during radiation or 
after radiation, but prior to chemotherapy [5]. 
Because of discouraging results using surgery, radia- 
tion, and chemotherapy as single modalities, combination 
approaches have been attempted. Simultaneous intra-arte- 
rial hepatic chemotherapy (bolus doxorubicin and con- 
tinuous infusion of fluorouracil) and radiation 
(1500-2400 cGy in 300-cGy fractions) has been investigated 
in 13 patients by Friedman et al. [14]. Six of the 13 patients 
(46%) had an objective response in this pilot study without 
significant toxicity, suggesting that this general approach 
may have some merit. Order and colleagues have used a 
combination of external-beam irradiation, radiolabeled 
anti-ferritin monoclonal antibodies, chemotherapy, and 
surgery with encouraging results [33], although it has been 
noted that the complexity of this regimen makes it difficult 
to determine the relative contributions of each form of 
treatment [31]. 
In an attempt to improve upon the results of intra-arte- 
rial chemotherapy alone for cancers metastatic to liver, 
some investigators have used combined intra-arterial che- 
motherapy and radiation for treatment (for review see 
[24]). Typically, the liver has been radiated to a total dose 
of 2500-3000 cGy with a single fraction of 200-300 cGy 
given per day. Chemotherapy (usually fluorouracil or 
FdUrd) has been given concurrently. The reported re- 
sponse rates have been in the range of 48-70%, but rigid 
criteria for judging a response usually are lacking. Overall, 
this treatment has been well tolerated. A recent study re- 
ports use of a schedule of hyperfractionated radiation, us- 
ing 150 cGy twice a day to a total dose of 2100 cGy [35]. 
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This was combined with hepatic arterial FdUrd in four pa- 
tients and intravenous fluorouracil in eight patients. Inter- 
pretation of this study is difficult owing to the small num- 
ber of patients and a lack of objective response criteria. 
However, two patients were alive without evidence of dis- 
ease at 24 months and toxicity was minimal. This study 
suggests that this may be a useful approach. 
Yttrium-90 mierospheres and tumor hypervaseularity 
As tumors grow, the evoked new capillary bed develops at 
the periphery, so that the most vascularized area is the out- 
er shell of the nodule [41]. Although the central core of 
many tumor nodules in the liver is hypovascular, the pe- 
riphery of the tumor nodule is generally hypervascular rel- 
ative to normal liver, as demonstrated by nuclear tomo- 
graphic scans after hepatic-arterial injection of TcMAA 
[16, 17]. The microvascular pattern is consistent with the 
distribution of tumor cell viability and growth, the central 
core of the tumor often being necrotic while the peripheral 
rim of actively proliferating tumor cells has an excellent 
blood supply [1, 41]. The density of vessels in the hypervas- 
cular regions of tumor nodules appears to be twofold to 
sixfold greater than in normal liver [10]. These observa- 
tions suggest that relative tumor hypervascularity might be 
used for selective therapeutic advantage with hepatic arte- 
rial injection of therapeutic microspheres. 
Microspheres of 20-80 ~tm diameter, when injected as 
a homogeneous suspension into the hepatic artery, should 
lodge in the hepatic arterial microvasculature in direct 
proportion to regional blood flow throughout that wa- 
tershed. As mentioned earlier, the hepatic-arterial injec- 
tion of TcMAA (lung scanning agent) with nuclear tomog- 
raphy provides a means to determine the relative blood 
flow distribution between normal liver and tumor nodules 
within liver and, thus, to monitor selective delivery of ther- 
apeutic microspheres to tumor [16]. 
A 22-~tm glass microsphere (TheraSphere) has been de- 
veloped in which yttrium-89 oxide is incorporated into the 
glass matrix and is activated by neutron bombardment to 
form the beta-emitting isotope yttrium-90 (90y) prior to use 
of the spheres as radiotherapeutic vehicles [42]. In dogs to 
which arterial 90y microspheres were administered at pro- 
gressively higher dosages, radiation exposures in excess of 
30000 rad did not cause total hepatic necrosis and were 
compatible with survival [42]. No microspheres distributed 
to the bone marrow and absolutely no myelosuppression 
were encountered in any animal. Using a protocol sup- 
ported by the dog studies, patients with hepatic tumors 
have received hepatic arterially administered Thera- 
Spheres. No significant toxicity has been demonstrated for 
absorbed doses between 5000 and 10000 rad to the liver 
and up to 20000 tad to the tumor (owing to tumor hyper- 
vascularity) [18, 20]. After dose-seeking phase I studies are 
complete, antitumor activity will be assessed at the maxi- 
mum tolerated dose (which appears to exceed 10000 tad). 
Conclusion 
A reasonable therapeutic aim is the development of new 
regimens for the treatment of primary and metastatic liver 
cancers that can efficiently (in 1-2 months of treatment) 
and effectively (complete response rate >80%) achieve 
eradication of surgically unresectable cancer. In this re- 
view, the potential for the development of new regimens 
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utilizing BrdUrd and IdUrd has been described. Combina-  
t ion of these potent radiosensitizers with 90y microspheres 
(both administered via the hepatic artery) may generate 
markedly improved selectivity and would represent a po- 
tent new approach to treatment. Toxicity studies in dogs 
indicate that such will be feasible without untoward hepat- 
ic toxicity [43]. Should such treatment prove effective in 
the clinic, a few patients with surgically unresectable he- 
patic cancer confined to the liver might be cured and 
many more with bulk hepatic tumor might achieve im- 
proved palliation. 
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